AI + EXCLUSIVE DATA

AI tracks executive moves from sources others don't have

Our proprietary AI analyzes exclusive hiring data to find decision-makers actively evaluating solutions like yours.

10-25 executive leads daily • Direct contact info • First 90 days targeting

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + proprietary hiring database

✓Executive contact details included

INDUSTRY FIRST

Twin Strand Biosciences Announces Executive Leadership Changes To Accelerate Adoption of Duplex Sequencing for Minimal Residual Disease (Mrd) Testing for Hematological Malignancies and Cell Therapy Monitoring

Aug 29, 2023•almost 2 years ago

Position

Chief Executive Officer

Company

TwinStrand Biosciences, Inc.

Ron Andrews

SeattleInformation Technology

Description

TwinStrand Biosciences®, the pioneer in Duplex Sequencing technology, which delivers accurate insights to researchers in applications ranging from residual cancer detection to genetic toxicology announced the appointment of Ron Andrews, as Chief Executive Officer and Board Member. TwinStrand® is also pleased to announce that David Canner, Partner at Soleus Capital, and Jason Myers, Independent Director, will join the TwinStrand Board of Directors. TwinStrand currently provides Duplex Sequencing assays for research use for minimal residual disease detection and genomic safety via the company's off-the-shelf kit solutions utilized on installed NGS platforms.

Company Information

Company

TwinStrand Biosciences, Inc.

Location

3131 ELLIOTT AVENUE

Seattle, Washington, United States

About

We are a vibrant young company committed to science first. Our mission is to develop and deliver the unprecedented accuracy of TwinStrand Duplex Sequencing™ technology for applications in clinical medicine and life sciences where it can do the greatest good for the greatest number of people. Our approach is multifaceted and encompasses internal development projects, external collaborations and empowering of partner organizations. TwinStrand Duplex Sequencing™ technology is an ultra-high accuracy, error-corrected sequencing method that overcomes the limitations of NGS by independently tracking both strands of individual DNA molecules. Utilizing our multi-patented novel chemistry and cloud-based bioinformatics, the paired sequences are compared to eliminate errors, reducing error rates from 1-in-100 to 1-in-10 million, revealing ultra-low frequency variants.

Company News

(5 articles)

Wed, 31 Jul 2024 07:00:00 GMT

TwinStrand Biosciences and Exact Sciences Announce Exclusive License Agreement for Duplex Sequencing Technology - PR Newswire

Wed, 31 Jul 2024 07:00:00 GMT

TwinStrand Biosciences and Exact Sciences Announce Exclusive License Agreement for Duplex Sequencing Technology - Stock Titan

Wed, 24 Apr 2024 07:00:00 GMT

TwinStrand Biosciences Initiates Regulatory Approval Process for Duplex Sequencing Mutagenesis Assays with OECD - PR Newswire

Tue, 29 Aug 2023 07:00:00 GMT

TwinStrand names Ron Andrews as permanent CEO after 2022 leadership shuffle - The Business Journals

Thu, 16 Nov 2023 08:00:00 GMT

Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease - Nature

FundzWatch™ Score

Medium Activity

3 total signals

Buyer Intent Analysis

Get personalized insights on buying likelihood

Related People

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months